Colorectal cancer (CRC) remains one of the most lethal cancers globally, ranking third in prevalence and second in cancer-related mortality. Although traditionally associated with older age groups, recent epidemiological trends uniquely show a worrying rise in CRC cases among those under 50. This early-onset form challenges conventional understanding and prompts urgent investigation into distinct causal mechanisms. The VHIO-led study breaks new ground by leveraging epigenomic data to decode environmental and lifestyle footprints embedded in DNA methylation patterns—chemical modifications marking genes without altering the underlying genetic code, thus regulating gene activity dynamically through life.

Epigenetics, as explained by José A. Seoane, the study’s principal investigator and head of VHIO’s Computational Biology Group, can be likened to a sophisticated annotation system layered on top of the genetic sequence. These methylation “marks” function like biological bookmarks, dictating which genes are expressed or silenced in response to external factors such as nutritional intake, chemical exposures, and behavioral habits. Critically, these epigenetic marks can accumulate or dissipate over time, capturing a timeline of environmental influences that conventional genetic analysis cannot reveal.

The research team meticulously compared methylation profiles derived from The Cancer Genome Atlas (TCGA) data, alongside nine independent patient cohorts, to distinguish epigenetic risk signatures between EOCRC patients and those diagnosed at later ages. Their refined analyses confirmed correlations with established risk factors including smoking cessation, dietary quality, and educational background. Most notably, however, the study identified a novel and striking link between the herbicide picloram—a chemical widely used in agricultural practices since the 1960s—and increased EOCRC risk.

This association was not merely inferential; the investigators harnessed extensive population-level datasets from the US National Cancer Institute’s SEER registries and pesticide application records from the US Geological Survey, identifying that counties with higher picloram usage exhibited significantly elevated EOCRC incidence rates, even after adjusting for sociodemographic variables and exposure to other pesticides. This critical finding suggests that long-term, relatively early-life exposure to picloram may be a plausible contributor to the molecular pathogenesis of colorectal tumors in younger populations.

On a molecular level, tumors from patients with presumed high picloram exposure demonstrated an unusual mutational landscape. In particular, there was a marked reduction in mutations affecting the APC gene—a central tumor suppressor gene that modulates the Wnt signaling pathway crucial for intestinal cell proliferation and homeostasis. This observation hints at an alternative, mutation-independent mechanism for carcinogenesis facilitated potentially by epigenetic reprogramming driven by toxic environmental insults such as picloram, fundamentally shifting the paradigm of colorectal cancer development.

The implications of these insights extend far beyond academic interest. By tracing an environmental footprint through epigenetic biomarkers, this study provides a powerful, novel framework for epidemiological surveillance and risk stratification, fostering earlier detection possibilities and refined prevention strategies tailored to environmental realities. The researchers emphasize that while confirming a causal relationship requires further experimentation and longitudinal follow-up, these findings underscore the urgency of reassessing pesticide policies and advocating for more stringent regulation to mitigate public health impacts.

This work also places a spotlight on the broader exposome concept as a key player in cancer disparities and disease heterogeneity. Until now, efforts to decipher modifiable risk factors unique to EOCRC have yielded limited, inconclusive results, hampered by methodological challenges in tracking lifelong exposures. The integration of epigenomic profiling circumvents these barriers, offering a precise molecular archive of environmental interactions that could revolutionize oncology research and public health interventions alike.

Moreover, the delineation of epigenetic signatures linked to lifestyle factors such as diet and smoking reaffirms the complex interplay of genetics, environment, and behavior in shaping cancer risk. This reinforces the message that multifactorial approaches targeting exposure reduction—from tobacco cessation campaigns to dietary improvements—remain fundamental pillars in the fight against colorectal cancer, especially among younger demographics.

The VHIO-led investigation was made possible through generous funding from the “la Caixa” Foundation and the Spanish Association Against Cancer, exemplifying successful collaborative efforts bridging computational biology, oncology, and epidemiology. As the scientific community digests these findings, there is an increasing call to expand research into how other environmental toxins may imprint on the epigenome, potentially influencing cancer susceptibility across diverse populations and cancer types.

In summary, this seminal study delivers a paradigm-shifting perspective on early-onset colorectal cancer etiology, by harnessing epigenetic biomarkers to trace historical environmental exposures. It highlights the imperative to incorporate exposomic data into cancer risk assessments and public health policy designs, aiming for targeted interventions that could curb the alarming rise of colorectal cancer in younger individuals worldwide.

Subject of Research: Environmental and lifestyle influences on early-onset colorectal cancer via epigenetic modifications.

Article Title: Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure.

News Publication Date: April 21, 2026

Web References:
https://doi.org/10.1038/s41591-026-04342-5

References:
Maas, S.C.E., Baraibar, I., Lemler, L., et al. Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure. Nat Med (2026).

Keywords: colorectal cancer, early-onset colorectal cancer, epigenetics, DNA methylation, exposome, pesticide exposure, picloram, APC gene, environmental risk factors, personalized medicine, cancer epidemiology, VHIO

Hepatocellular carcinoma remains a formidable global health challenge, constituting approximately 90% of primary liver cancers and ranking as the fourth leading cause of cancer-related mortality worldwide. The heterogeneous nature of HCC, coupled with its notorious resistance to standard therapies, stems largely from intricate epigenetic reprogramming, particularly DNA methylation alterations that silence tumor suppressors while activating oncogenes. Despite advances, the precise molecular crosstalk between these epigenetic changes and the immune system’s role in disease progression has been elusive—until now.

This study capitalized on integrated datasets, merging DNA methylation profiles from the Cancer Genome Atlas (TCGA-LIHC) with comprehensive genome-wide association study (GWAS) summary statistics focusing on white blood cell counts. Through a robust two-sample Mendelian randomization (MR) approach, the investigators systematically assessed how HCC-related CpG methylation sites may causally influence variations in white blood cell populations. The MR framework, leveraging genetic variants as instrumental variables, provides a powerful tool to infer causality beyond mere association, a crucial advancement in cancer epigenetics research.

After rigorous statistical filtering and multiple sensitivity analyses, the researchers identified 26 CpG sites intricately linked to white blood cell modulation within the HCC context. These methylation sites were not arbitrary markers; Bayesian colocalization analysis confirmed their positional overlap with expression quantitative trait loci (eQTLs), providing functional evidence that methylation dynamics at these loci directly impact gene expression patterns. Subsequent tumor-specific transcriptomic validation further narrowed the focus to three core genes, underscoring their pivotal roles in shaping the immune microenvironment.

Central to these findings is BTN3A2, a gene previously unappreciated in HCC immunology but here revealed as a potent regulator of lymphocyte and neutrophil counts. BTN3A2 belongs to the butyrophilin family, known for its immunomodulatory functions, particularly in adaptive immunity and T-cell activation. Its epigenetic regulation appears to orchestrate immune cell influx and function within the HCC tumor microenvironment, suggesting BTN3A2 modulation could recalibrate antitumor immunity.

Alongside BTN3A2, TRIM27 emerges as a crucial immunometabolic checkpoint. TRIM27, part of the tripartite motif-containing protein family, is implicated in diverse cellular processes, including ubiquitination and transcriptional regulation, often with oncogenic or immunoregulatory consequences. In HCC, TRIM27’s epigenetically driven expression shapes metabolic and immune signaling axes, potentially fostering an immunosuppressive niche that allows tumor persistence and progression.

Moreover, S100A12—a calcium-binding protein linked to innate immune responses—was identified as a key modulator influencing systemic inflammation and neutrophil activity. Its methylation-mediated deregulation in HCC impacts not only local tumor immunity but also the broader systemic immune profile, highlighting the interconnectedness of epigenetic control and immune surveillance mechanisms in cancer.

This trio of genes represents a nexus where epigenetic alterations converge on immune regulation, revealing mechanisms by which HCC tumors may manipulate host immunity to evade eradication. The delineation of such methylation-immune axes advances our understanding of tumor immunobiology, with implications extending to prognostication and targeted therapy development. For instance, epigenetic therapies such as DNA methyltransferase inhibitors could be fine-tuned to restore normal methylation patterns at these loci, reversing immune dysfunction.

The study’s use of transcriptome-wide association study (TWAS) analysis further enriched the robustness of their conclusions. TWAS allowed gene-level validation, independently corroborating the regulatory impact of these methylation changes on gene expression relevant to immune cell counts. By integrating genomic, epigenomic, and transcriptomic data layers, the research sets a new benchmark for dissecting cancer-immune interactions.

Importantly, the clinical relevance of white blood cell counts as prognostic markers in HCC has long been acknowledged, but this study unveils the underlying causal epigenetic drivers. Peripheral immune parameters, often altered in HCC patients, now emerge not merely as symptomatic correlates but as reflections of tumor-intrinsic epigenetic remodeling. This insight transforms peripheral white blood cells from passive indicators to active participants in tumor progression, mediated by epigenetic regulation.

The findings also underscore the dynamic immunomodulatory capacity of HCC tumors, which secrete cytokines and reshape systemic immunity through aberrant epigenetic marks. This systemic impact broadens the spatial scope of tumor-immune interactions beyond the local microenvironment, suggesting that successful therapies may need to address both tumor-intrinsic mechanisms and systemic immune recalibration.

By targeting the epigenome-immune crosstalk, novel combination therapies hold promise to overcome the limitations of current immune checkpoint inhibitors, which often fail due to immunosuppressive tumor milieus in advanced HCC. Epigenetic drugs designed to modulate key methylation sites identified in this study may unlock immune activation, paving the way for more effective immunotherapies.

This integrative approach epitomizes precision oncology’s future—leveraging multidisciplinary data and advanced analytical techniques to uncover causative molecular underpinnings rather than mere associations. The use of Mendelian randomization to infer causality in epigenetic-immunological interplay may inspire similar studies across diverse cancer types, further enhancing the therapeutic arsenal.

In sum, the identification of BTN3A2, S100A12, and TRIM27 as central methylation-immunoregulatory hubs in HCC represents a breakthrough in our understanding of cancer-immune dynamics. The study not only expands the molecular landscape of hepatocarcinogenesis but also provides a rational framework for designing epigenetic-immunotherapeutic strategies aimed at reversing immune suppression and improving patient survival.

As hepatocellular carcinoma continues to pose a formidable challenge to global health, integrating epigenetic insights with immunological parameters emerges as a promising frontier. This pioneering Mendelian randomization study offers a beacon of hope, illuminating pathways by which precision epigenetic modulation could transform the current therapeutic paradigm, ultimately turning the tide against this devastating disease.

Subject of Research:
Epigenetic regulation and immune cell dynamics in hepatocellular carcinoma, focusing on DNA methylation-driven modulation of white blood cell counts.

Article Title:
Decoding the epigenetic-immune nexus in hepatocellular carcinoma: a Mendelian randomization study reveals BTN3A2, S100A12 and TRIM27 as white blood cell regulators.

Article References:
Qiu, Y., Zhang, H., Yu, X. et al. Decoding the epigenetic-immune nexus in hepatocellular carcinoma: a Mendelian randomization study reveals BTN3A2, S100A12 and TRIM27 as white blood cell regulators. BMC Cancer 25, 1282 (2025). https://doi.org/10.1186/s12885-025-14693-w

Image Credits: Scienmag.com

DOI:
https://doi.org/10.1186/s12885-025-14693-w